94056-98-1

Basic information

• Product Name: 1-(4-Aminophenoxy)-3-ethoxy-2-propanol
• Synonyms: 1-(4-Aminophenoxy)-3-ethoxy-2-propanol;4-[3-Ethoxy-2-(hydroxyl)propoxy]aniline;1-(4-AMinophenoxy)-3;1-(4-AMinophenoxy)-3-ethoxypropan-2-ol
• CAS NO: 94056-98-1
• Molecular Formula: C₁₁H₁₇NO₃
• Molecular Weight: 211.26
• Mol File: 94056-98-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 386.31 °C at 760 mmHg
• Flash Point: 187.434 °C
• Appearance: /
• Density: 1.135
• Storage Temp.: 2-8°C
• PKA: 13.67±0.20(Predicted)
• CAS DataBase Reference: 1-(4-Aminophenoxy)-3-ethoxy-2-propanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Aminophenoxy)-3-ethoxy-2-propanol(94056-98-1)
• EPA Substance Registry System: 1-(4-Aminophenoxy)-3-ethoxy-2-propanol(94056-98-1)

Safety Data

• Hazardous Substances Data: 94056-98-1(Hazardous Substances Data)

Usage

General Description

1-(4-Aminophenoxy)-3-ethoxy-2-propanol is a chemical compound that is commonly used in pharmaceutical and research applications. It is an organic compound with the molecular formula C11H17NO3 and a molecular weight of 211.25 g/mol. 1-(4-Aminophenoxy)-3-ethoxy-2-propanol is a derivatized catecholamine and is often used as a precursor in the synthesis of various pharmaceuticals and biologically active compounds. It is known for its ability to modify the adrenergic system and has been studied for its potential therapeutic applications in the treatment of various medical conditions. Overall, 1-(4-Aminophenoxy)-3-ethoxy-2-propanol is a versatile chemical that has a wide range of applications in the fields of medicine and research.

Upstream product

• 94925-71-0 1-Ethoxy-3-(4-nitro-phenoxy)-propan-2-ol 
• 4016-11-9 2-(ethoxymethyl)oxirane 
• 4151-98-8 1-ethoxy-3-chloro-propan-2-ol 
• 100-02-7 4-nitro-phenol 
• 125228-75-3 4-nitrophenyl 2-oxiranylmethyl ether 

Downstream Products

• 160114-16-9 2-{4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl}ethyl methyl sulfide 
• 215030-53-8 (+/-)-1-bromo-2-[4-(2-hydroxy-3-ethoxypropoxy)phenylcarbamoyl]ethane 
• 215030-54-9 (+/-)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]dimethylamine 
• 94055-76-2 suplatast tosilate 
• 100548-98-9 Acetic acid 1-ethoxymethyl-2-[4-(3-methylsulfanyl-propionylamino)-phenoxy]-ethyl ester 

Relevant articles and documents

Mechanism of preferential enrichment, an unusual enantiomeric resolution phenomenon caused by polymorphic transition during crystallization of mixed crystals composed of two enantiomers

The mechanism of Preferential Enrichment, an unusual enantiomeric resolution phenomenon observed upon recrystallization of a series of racemic crystals which are classified as a racemic mixed crystal with fairly ordered arrangement of the two enantiomers, has been studied. On the basis of the existence of polymorphs and the occurrence of the resulting polymorphic transition during crystallization from solution, the mechanism has been accounted for in terms of (1) a preferential homochiral molecular association to form one-dimensional chain structures in the supersaturated solution of the racemate or nonracemic sample with a low ee value, (2) a kinetic formation of a metastable crystalline phase retaining the homochiral chain structures in a process of nucleation, (3) a polymorphic transition from the metastable phase to a stable one followed by enantioselective liberation of the excess R (or S) enantiomers from the transformed crystal into solution at the beginning of crystal growth to result in a slight enrichment (up to 10% ee) of the opposite S (or R) enantiomer in the deposited crystals, together with an enantiomeric enrichment of the R (or S) enantiomer in the mother liquor, and (4) a chiral discrimination by the once formed S (or R)-rich stable crystalline phase in a process of the subsequent crystal growth, leading to a considerable enantiomeric enrichment of the R (or S) enantiomer up to 100% ee in the mother liquor. The processes (3) and (4) are considered to be directly responsible for an enrichment of one enantiomer in the mother liquor. The association mode of the two enantiomers in solution has been investigated by means of (i) the solubility measurement and (ii) the number-averaged molecular weight measurement in solution by vapor pressure osmometry, together with (iii) the molecular dynamics simulation of oligomer models. The polymorphic transition during crystallization has been observed visually and by means of the in situ FTIR technique and DSC measurement. Both metastable and stable crystals have been obtained, and their crystal structures have been elucidated by X-ray crystallographic analysis of their single crystals.